Updated findings from the PERSEUS study found that patients with newly diagnosed multiple myeloma benefited from a treatment ...

Among patients who became MRD negative at a 10-5 sensitivity, 38.6% in the D-VRd arm had sustained MRD negativity vs 17.4% in the control arm (P = .0006). At the 10 -6 sensitivity, these ...

A Darzalex-based regiment improved MRD negativity rates while sustaining MRD negativity compared with VRd in patients with ...

Telo Genomics Corp. (TSXV: TELO) (OTCQB: TDSGF) (the “Company” or “Telo”) a biotech company developing the industry’s leading ...

Undetectable measurable residual disease rates can help predict progression-free survival in patients with chronic ...

Based on my last bone marrow biopsy in June 2023, I am grateful to be in complete remission. In the world of multiple myeloma, minimal residual disease (MRD; amount of cancer that remains in the body) ...

The news that Patti Scialfa, Bruce Springsteen’s wife and bandmate, has multiple myeloma is bringing attention to the rare blood cancer. In the new documentary “Road Diary: Bruce Springsteen ...

transplant-eligible patients with multiple myeloma. The IsKia trial showed that 77% of the Sarclisa group achieved minimal residual disease (MRD) negativity at the end of the induction and ...

Certain genetic changes, or mutations, can increase the chances of leukemia or blood cancer. According to experts, leukemia, ...

Japan’s MHLW accepts for review GSK’s NDA for Blenrep combinations in relapsed/refractory multiple myeloma: London, UK Wednesday, September 18, 2024, 10:00 Hrs [IST] GSK plc a ...

Telo's MRD clinical trials with McGill University have two objectives that will potentially enable the development of two prognostic tests for monitoring myeloma MRD. The two objectives include ...